ertapenem 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
analogues of penicillanic acid antibiotics modified in the five-membered ring 1046 153832-46-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ertapenem
  • invanz
  • ertapenem sodium
Ertapenem has in vitro activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3.
  • Molecular weight: 475.52
  • Formula: C22H25N3O7S
  • CLOGP: -0.83
  • LIPINSKI: 0
  • HAC: 10
  • HDO: 5
  • TPSA: 156.27
  • ALOGS: -3.22
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 38 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 28.72 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 %
Vd (Volume of distribution) 0.12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.45 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.10 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.80 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.941 Moderate 0.79
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.668 Moderate 0.79
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.179 10^-6 cm/s Moderate 0.79
dh-clint Dog hepatocyte intrinsic clearance 1.600 uL/min/10^6 cells Moderate 0.79
dppb Dog plasma protein binding (% unbound) 52.650 % Moderate 0.79
fcs-ppb Fetal calf serum protein binding (% unbound) 54.650 % Moderate 0.79
herg hERG pIC50 4.584 pIC50 Moderate 0.79
hh-clint Human hepatocyte intrinsic clearance 2.259 uL/min/10^6 cells Moderate 0.79
hlm-clint Human liver microsomal intrinsic clearance 3.741 uL/min/mg protein Moderate 0.79
hppb Human plasma protein binding (% unbound) 31.020 % Moderate 0.79
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PIK3CB,PIM2,PRKDC,STK33,SYK,TEK,TGFBR1,ZAP70 36
kinase-selectivity-class ACVR2B,AXL,BRAF,CDK9,DYRK1B,EIF2AK3,GRK2,MAP2K6,MAPK7,PRKDC,STK33,TEK 12
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.259 Moderate 0.79
mh-clint Mouse hepatocyte intrinsic clearance 6.412 Moderate 0.79
mppb Mouse plasma protein binding (% unbound) 63.740 Moderate 0.79
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.231 Moderate 0.79
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 43.250 % Moderate 0.79
rh-clint Rat hepatocyte intrinsic clearance 3.715 uL/min/10^6 cells Moderate 0.79
rh-fuinc Rat hepatocyte fraction unbound in incubation 88.930 % Moderate 0.79
rppb Rat plasma protein binding (% unbound) 27.920 % Moderate 0.79
solubility-dd Solubility at pH 7.4 in DMSO 860.994 uM Moderate 0.79

Approvals:

DateAgencyCompanyOrphan
April 18, 2002 EMA Merck Sharp & Dohme Ltd
Nov. 21, 2001 FDA MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 1430.53 26.59 406 10427 37564 90580050
Chronic sinusitis 476.62 26.59 157 10676 23645 90593969
Paraesthesia oral 444.01 26.59 160 10673 31499 90586115
Vaginal flatulence 424.77 26.59 124 10709 12514 90605100
Proctitis 401.71 26.59 124 10709 15135 90602479
Female genital tract fistula 390.60 26.59 126 10707 17742 90599872
Radiculopathy 382.22 26.59 125 10708 18380 90599234
Vaginal discharge 372.02 26.59 124 10709 19340 90598274
Procedural pain 355.90 26.59 138 10695 33222 90584392
Oral candidiasis 309.75 26.59 127 10706 35328 90582286
Drug ineffective 255.15 26.59 527 10306 1383771 89233843
Frequent bowel movements 246.28 26.59 125 10708 56810 90560804
Colitis ulcerative 239.56 26.59 125 10708 60141 90557473
Colitis 233.02 26.59 129 10704 69813 90547801
Haematochezia 223.19 26.59 126 10707 70787 90546827
Rectal haemorrhage 205.15 26.59 126 10707 82618 90534996
Therapeutic product effect incomplete 175.12 26.59 161 10672 193735 90423879
Seizure 162.18 26.59 139 10694 152490 90465124
Dyspepsia 136.65 26.59 142 10691 198018 90419596
Hallucination 118.17 26.59 82 10751 65877 90551737
Product use in unapproved indication 116.14 26.59 170 10663 336066 90281548
Erythema 111.44 26.59 137 10696 229109 90388505
Encephalopathy 108.10 26.59 68 10765 46376 90571238
Pyrexia 103.64 26.59 237 10596 660248 89957366
Weight decreased 96.57 26.59 167 10666 379743 90237871
Anaemia 89.53 26.59 155 10678 352647 90264967
Constipation 84.29 26.59 133 10700 280262 90337352
Abdominal pain 69.75 26.59 149 10684 395572 90222042
Epilepsy 69.68 26.59 66 10767 82140 90535474
Disorganised speech 65.50 26.59 19 10814 1866 90615748
Infusion related reaction 62.32 26.59 147 10686 416633 90200981
Clostridium difficile colitis 61.86 26.59 39 10794 26667 90590947
Renal graft infection 54.79 26.59 12 10821 374 90617240
Clostridium difficile infection 53.30 26.59 40 10793 36205 90581409
Malaise 52.14 26.59 171 10662 585815 90031799
Confusional state 51.08 26.59 130 10703 386075 90231539
Status epilepticus 49.92 26.59 30 10803 18844 90598770
Clostridium test positive 49.33 26.59 20 10813 5381 90612233
Fatigue 48.87 26.59 40 10793 1153983 89463631
Mitochondrial toxicity 48.33 26.59 12 10821 651 90616963
Mental status changes 47.97 26.59 41 10792 44638 90572976
Arthralgia 45.75 26.59 18 10815 778504 89839110
Avian influenza 45.27 26.59 8 10825 78 90617536
Off label use 44.51 26.59 253 10580 1101999 89515615
Skin odour abnormal 44.42 26.59 14 10819 1821 90615793
Generalised tonic-clonic seizure 43.66 26.59 35 10798 34868 90582746
Raoultella ornithinolytica infection 43.60 26.59 8 10825 98 90617516
Hallucination, visual 39.66 26.59 28 10805 23064 90594550
Neurotoxicity 39.14 26.59 27 10806 21440 90596174
Wound secretion 37.24 26.59 16 10817 4974 90612640
Band neutrophil count decreased 35.90 26.59 7 10826 121 90617493
Drug reaction with eosinophilia and systemic symptoms 35.58 26.59 34 10799 42724 90574890
Abdominal discomfort 35.49 26.59 7 10826 477321 90140293
Nasopharyngitis 34.76 26.59 4 10829 407100 90210514
Acute generalised exanthematous pustulosis 34.23 26.59 21 10812 13682 90603932
Delirium 33.36 26.59 51 10782 104308 90513306
Pathogen resistance 32.66 26.59 17 10816 8098 90609516
Alopecia 31.51 26.59 10 10823 495061 90122553
Bone marrow eosinophilic leukocyte count increased 30.88 26.59 5 10828 27 90617587
Allergic hepatitis 29.53 26.59 5 10828 37 90617577
Hypersensitivity 29.26 26.59 9 10824 454668 90162946
Pain in extremity 28.85 26.59 9 10824 450520 90167094
Toxic encephalopathy 28.79 26.59 16 10817 8683 90608931
Synovitis 28.75 26.59 3 10830 329749 90287865
Tooth discolouration 28.41 26.59 9 10824 1189 90616425
Weight increased 27.38 26.59 8 10825 417919 90199695
Seizure like phenomena 27.10 26.59 9 10824 1381 90616233

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Confusional state 285.87 24.04 229 6797 167368 42446941
Product use in unapproved indication 236.42 24.04 214 6812 184242 42430067
Seizure 227.29 24.04 175 6851 120386 42493923
Hallucination 179.78 24.04 114 6912 57393 42556916
Epilepsy 170.16 24.04 84 6942 26087 42588222
Pathogen resistance 160.15 24.04 63 6963 11387 42602922
Encephalopathy 154.80 24.04 92 6934 41241 42573068
Toxic encephalopathy 117.78 24.04 44 6982 6909 42607400
Delirium 115.94 24.04 84 6942 52435 42561874
Hallucination, visual 111.94 24.04 59 6967 20961 42593348
Myoclonus 108.55 24.04 54 6972 17011 42597298
Clostridium difficile colitis 108.51 24.04 58 6968 21194 42593115
Disorganised speech 78.09 24.04 22 7004 1406 42612903
Drug resistance 73.75 24.04 54 6972 34194 42580115
Generalised tonic-clonic seizure 71.75 24.04 48 6978 26331 42587978
Status epilepticus 67.05 24.04 38 6988 15540 42598769
Neurotoxicity 66.65 24.04 44 6982 23607 42590702
Clostridium test positive 62.19 24.04 26 7000 5479 42608830
Disorientation 49.78 24.04 44 6982 36345 42577964
Malacoplakia 49.46 24.04 14 7012 910 42613399
Agitation 47.95 24.04 56 6970 64258 42550051
Drug reaction with eosinophilia and systemic symptoms 46.19 24.04 45 6981 42030 42572279
Biliary sepsis 40.56 24.04 12 7014 912 42613397
Dysarthria 38.95 24.04 40 6986 39767 42574542
Serotonin syndrome 38.88 24.04 33 6993 25812 42588497
Drug interaction 38.86 24.04 114 6912 266885 42347424
Urinary tract inflammation 34.26 24.04 8 7018 240 42614069
Neuromyopathy 34.02 24.04 11 7015 1123 42613186
Mental disorder 33.40 24.04 26 7000 18003 42596306
Conductive deafness 33.03 24.04 9 7017 508 42613801
Myasthenia gravis crisis 32.87 24.04 10 7016 836 42613473
Pseudomonal sepsis 31.68 24.04 15 7011 4234 42610075
Neutropenia 29.78 24.04 86 6940 199345 42414964
Eosinophilic pneumonia acute 28.96 24.04 9 7017 808 42613501
Rash morbilliform 28.95 24.04 14 7012 4139 42610170
Eosinophilia 28.51 24.04 31 6995 32868 42581441
Appendicitis perforated 27.37 24.04 11 7015 2095 42612214
Mental status changes 27.01 24.04 34 6992 42081 42572228
Eosinophilic pneumonia 26.83 24.04 14 7012 4860 42609449
Arterial angioplasty 26.57 24.04 5 7021 50 42614259
Vitamin B1 deficiency 25.42 24.04 7 7019 411 42613898
Anticonvulsant drug level decreased 25.38 24.04 9 7017 1216 42613093
Foot amputation 24.44 24.04 8 7018 849 42613460
Incorrect product administration duration 24.37 24.04 14 7012 5866 42608443

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 459.36 22.32 158 16466 21501 110551174
Chronic sinusitis 425.47 22.32 155 16469 24929 110547746
Vaginal flatulence 397.14 22.32 123 16501 12021 110560654
Paraesthesia oral 391.44 22.32 158 16466 33513 110539162
Female genital tract fistula 367.78 22.32 125 16499 16394 110556281
Proctitis 357.01 22.32 123 16501 16804 110555871
Vaginal discharge 350.22 22.32 123 16501 17785 110554890
Radiculopathy 344.76 22.32 124 16500 19212 110553463
Seizure 317.85 22.32 264 16360 220921 110351754
Procedural pain 309.99 22.32 136 16488 35429 110537246
Product use in unapproved indication 308.75 22.32 357 16267 447020 110125655
Hallucination 292.87 22.32 185 16439 101247 110471428
Oral candidiasis 262.14 22.32 130 16494 44630 110528045
Confusional state 261.48 22.32 336 16288 468344 110104331
Encephalopathy 252.01 22.32 155 16469 80900 110491775
Epilepsy 205.77 22.32 148 16476 100061 110472614
Frequent bowel movements 190.56 22.32 124 16500 71266 110501409
Colitis ulcerative 176.76 22.32 122 16502 77241 110495434
Pathogen resistance 171.69 22.32 73 16551 17599 110555076
Clostridium difficile colitis 168.12 22.32 96 16528 43682 110528993
Colitis 165.39 22.32 131 16493 102192 110470483
Haematochezia 157.58 22.32 134 16490 115390 110457285
Hallucination, visual 141.83 22.32 83 16541 39522 110533153
Disorganised speech 136.10 22.32 40 16584 3263 110569412
Delirium 135.82 22.32 132 16492 134893 110437782
Rectal haemorrhage 133.57 22.32 124 16500 119709 110452966
Therapeutic product effect incomplete 123.63 22.32 160 16464 223645 110349030
Myoclonus 117.74 22.32 69 16555 32929 110539746
Dyspepsia 117.34 22.32 144 16480 190821 110381854
Toxic encephalopathy 115.95 22.32 53 16571 15161 110557514
Clostridium test positive 112.48 22.32 47 16577 10846 110561829
Status epilepticus 109.97 22.32 65 16559 31506 110541169
Generalised tonic-clonic seizure 108.14 22.32 79 16545 54601 110518074
Neurotoxicity 104.53 22.32 70 16554 42137 110530538
Pyrexia 98.37 22.32 327 16297 897938 109674737
Drug resistance 88.51 22.32 71 16553 56303 110516372
Clostridium difficile infection 78.34 22.32 64 16560 52065 110520610
Drug reaction with eosinophilia and systemic symptoms 78.29 22.32 78 16546 82017 110490658
Fatigue 73.89 22.32 46 16578 1215912 109356763
Erythema 73.87 22.32 146 16478 291301 110281374
Mental status changes 70.15 22.32 71 16553 76051 110496624
Drug ineffective 60.34 22.32 412 16212 1520128 109052547
Anaemia 59.50 22.32 199 16425 546887 110025788
Arthralgia 58.67 22.32 22 16602 779610 109793065
Infusion related reaction 56.84 22.32 155 16469 381007 110191668
Weight decreased 55.15 22.32 175 16449 467882 110104793
Joint swelling 51.44 22.32 4 16620 442841 110129834
Disorientation 51.14 22.32 58 16566 70613 110502062
Malacoplakia 50.87 22.32 15 16609 1237 110571438
Constipation 46.03 22.32 138 16486 357648 110215027
Renal graft infection 43.68 22.32 12 16612 767 110571908
Off label use 42.42 22.32 376 16248 1499809 109072866
Eosinophilic pneumonia 42.29 22.32 21 16603 7206 110565469
Agitation 41.98 22.32 67 16557 112984 110459691
Avian influenza 40.71 22.32 8 16616 113 110572562
Pain in extremity 39.63 22.32 12 16612 487106 110085569
Granulomatous dermatitis 38.48 22.32 10 16614 516 110572159
Conductive deafness 38.48 22.32 9 16615 299 110572376
Nasopharyngitis 37.41 22.32 7 16617 394354 110178321
Raoultella ornithinolytica infection 37.32 22.32 8 16616 177 110572498
Abdominal pain 37.09 22.32 164 16460 512825 110059850
Weight increased 36.65 22.32 9 16615 419635 110153040
Metabolic encephalopathy 36.49 22.32 22 16602 11038 110561637
Dyspnoea 34.35 22.32 72 16552 1106800 109465875
Band neutrophil count decreased 34.30 22.32 7 16617 121 110572554
Skin odour abnormal 33.68 22.32 13 16611 2441 110570234
Alopecia 33.49 22.32 7 16617 364746 110207929
Endotracheal intubation 33.45 22.32 17 16607 6127 110566548
Acute generalised exanthematous pustulosis 31.29 22.32 26 16598 21638 110551037
Eosinophilia 31.26 22.32 41 16583 57895 110514780
Urinary tract inflammation 31.23 22.32 8 16616 390 110572285
Neutropenia 31.13 22.32 125 16499 374495 110198180
Eosinophilic pneumonia acute 30.87 22.32 11 16613 1654 110571021
Synovitis 30.39 22.32 3 16621 274089 110298586
Neuromyopathy 30.16 22.32 11 16613 1768 110570907
Vomiting 30.15 22.32 57 16567 910618 109662057
Biliary sepsis 29.78 22.32 11 16613 1832 110570843
Abdominal discomfort 29.76 22.32 11 16613 393847 110178828
Bone marrow eosinophilic leukocyte count increased 29.58 22.32 5 16619 28 110572647
Cross sensitivity reaction 29.14 22.32 15 16609 5552 110567123
Tooth discolouration 29.09 22.32 10 16614 1353 110571322
Escherichia test positive 28.93 22.32 13 16611 3571 110569104
Wound secretion 28.82 22.32 16 16608 6885 110565790
General physical health deterioration 28.74 22.32 14 16610 425281 110147394
Dysarthria 28.71 22.32 48 16576 84073 110488602
Vitamin B1 deficiency 28.25 22.32 9 16615 961 110571714
Stomatitis 27.39 22.32 4 16620 270238 110302437
Allergic hepatitis 27.13 22.32 5 16619 49 110572626
Arterial angioplasty 27.03 22.32 5 16619 50 110572625
Mitochondrial toxicity 26.93 22.32 12 16612 3233 110569442
Seizure like phenomena 26.78 22.32 11 16613 2430 110570245
Myasthenia gravis crisis 26.30 22.32 10 16614 1804 110570871
Peripheral swelling 26.26 22.32 14 16610 404020 110168655
Lower respiratory tract infection 26.08 22.32 3 16621 243103 110329572
Erythema multiforme 25.75 22.32 23 16601 21074 110551601
Anxiety 25.46 22.32 10 16614 345068 110227607
Product preparation issue 25.40 22.32 11 16613 2768 110569907
Back pain 25.39 22.32 12 16612 370984 110201691
Unresponsive to stimuli 25.33 22.32 39 16585 63751 110508924
Malaise 25.21 22.32 180 16444 671639 109901036
Hypoaesthesia 25.08 22.32 8 16616 314215 110258460
Anticonvulsant drug level decreased 24.71 22.32 10 16614 2126 110570549
Swelling 24.57 22.32 11 16613 351030 110221645
Urinary tract infection pseudomonal 24.33 22.32 10 16614 2212 110570463
Rash morbilliform 24.15 22.32 15 16609 7936 110564739
Mental disorder 23.37 22.32 29 16595 38762 110533913
Foot amputation 23.00 22.32 8 16616 1120 110571555
Hallucinations, mixed 22.92 22.32 15 16609 8678 110563997
Abdominal pain upper 22.82 22.32 12 16612 349099 110223576
Wound 22.57 22.32 4 16620 234433 110338242
Contusion 22.42 22.32 4 16620 233357 110339318

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DH03 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Carbapenems
FDA CS M0024174 Carbapenems
FDA EPC N0000175496 Penem Antibacterial
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:36047 antibacterial drug

Related Drugs by ATC class:

J01DH Carbapenems 10 drugs
betamipronbiapenemcilastatindoripenemimipenemmeropenempanipenemrelebactamtebipenem pivoxilvaborbactam

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute bacterial peritonitis indication 31860008
Bacterial pneumonia indication 53084003 DOID:874
Miscarriage with sepsis indication 67465009
Haemophilus influenzae pneumonia indication 70036007
Abdominal abscess indication 75100008
Female genital tract infection indication 125585007
Infectious disease of abdomen indication 128070006
Pneumococcal pneumonia indication 233607000
Escherichia coli urinary tract infection indication 301011002
Community acquired pneumonia indication 385093006
Peptostreptococcus infection indication 135341000119101
Urinary tract infection caused by Klebsiella indication 369001000119100
Complicated Skin and Skin Structure Streptococcus Pyogenes Infection indication
Septic Abortion due to Porphyromonas indication
Post-Op Gynecologic Infection due to Porphyromonas indication
Klebsiella Pyelonephritis indication
Post-Op Gynecological Peptostreptococcus Infection indication
Complicated E. Coli Peritonitis indication
Postpartum Endomyometritis due to E. Coli indication
Colorectal Surgery Infection Prevention indication
Diabetic Foot Infection indication
Streptococcal Septic Abortion indication
Postpartum Endomyometritis due to Peptostreptococcus indication
Post-Op Gynecologic Infection due to Bacteroides indication
Postpartum Endomyometritis due to Bacteroides indication
E. Coli Septic Abortion indication
E. Coli Pyelonephritis indication
Complicated Skin and Skin Structure Staphylococcus Aureus Infection indication
Complicated Skin and Skin Structure E. Coli Infection indication
Peptostreptococcus Septic Abortion indication
Complicated Bacterial Peritonitis indication
Complicated Bacteroides Peritonitis indication
Moraxella Catarrhalis Pneumonia indication
Post-Op Gynecologic Infection due to Prevotella indication
Bacteroides Septic Abortion indication
Post-Op Gynecological Infection due to E. Coli indication
Postpartum Endomyometritis due to Porphyromonas indication
Postpartum Endomyometritis due to Streptococcus indication
Postpartum Endomyometritis due to Prevotella indication
Post-Op Gynecologic Infection, due to Streptococcus indication
Prevotella Septic Abortion indication
Complicated Skin and Skin Structure Infection indication
Gas gangrene caused by clostridium perfringens off-label use 266093005
Clostridium Perfringens Empyema off-label use
Acute nephropathy contraindication 58574008
Kidney disease contraindication 90708001 DOID:557
Seizure disorder contraindication 128613002
Lesion of brain contraindication 301766008
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.79 acidic
pKa2 4.1 acidic
pKa3 6.83 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D-alanyl-D-alanine carboxypeptidase DacB Enzyme INHIBITOR DRUGBANK CHEMBL
Penicillin-binding protein 1A Enzyme INHIBITOR DRUGBANK CHEMBL
Penicillin-binding protein 1B Enzyme INHIBITOR DRUGBANK CHEMBL
Penicillin-binding protein 1 Enzyme WOMBAT-PK
Penicillin-binding protein 2 Enzyme WOMBAT-PK
D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase penicillin-binding protein 6 Enzyme WOMBAT-PK
Penicillin-binding protein 4 Enzyme WOMBAT-PK
D-ala-D-ala-carboxypeptidase; D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase family protein; Penicillin-binding protein 5 Enzyme WOMBAT-PK

External reference:

IDSource
4021283 VUID
N0000148720 NUI
D04049 KEGG_DRUG
153773-82-1 SECONDARY_CAS_RN
4021283 VANDF
C1120106 UMLSCUI
CHEBI:404903 CHEBI
6H7 PDB_CHEM_ID
CHEMBL1359 ChEMBL_ID
CHEMBL1232 ChEMBL_ID
D000077727 MESH_DESCRIPTOR_UI
DB00303 DRUGBANK_ID
10906 IUPHAR_LIGAND_ID
8049 INN_ID
G32F6EID2H UNII
150610 PUBCHEM_CID
325642 RXNORM
16218 MMSL
173352 MMSL
274067 MMSL
42474 MMSL
d04783 MMSL
009554 NDDF
009555 NDDF
385573008 SNOMEDCT_US
385574002 SNOMEDCT_US
396346003 SNOMEDCT_US
G32F6EID2H INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
INVANZ HUMAN PRESCRIPTION DRUG LABEL 1 0006-3843 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAMUSCULAR NDA 28 sections
INVANZ HUMAN PRESCRIPTION DRUG LABEL 1 0006-3843 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAMUSCULAR NDA 28 sections
INVANZ HUMAN PRESCRIPTION DRUG LABEL 1 0006-3845 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAVENOUS NDA 28 sections
INVANZ HUMAN PRESCRIPTION DRUG LABEL 1 0006-3845 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAVENOUS NDA 28 sections
ertapenem sodium HUMAN PRESCRIPTION DRUG LABEL 1 0143-9398 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 28 sections
Ertapenem HUMAN PRESCRIPTION DRUG LABEL 1 0143-9429 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 28 sections
Ertapenem HUMAN PRESCRIPTION DRUG LABEL 1 0409-3510 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 28 sections
ERTAPENEM SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 16714-889 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAVENOUS ANDA 25 sections
Ertapenem HUMAN PRESCRIPTION DRUG LABEL 1 25021-199 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAVENOUS ANDA 32 sections
Ertapenem HUMAN PRESCRIPTION DRUG LABEL 1 25021-199 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAVENOUS ANDA 32 sections
ERTAPENEM HUMAN PRESCRIPTION DRUG LABEL 1 42023-221 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAMUSCULAR NDA 29 sections
ERTAPENEM HUMAN PRESCRIPTION DRUG LABEL 1 42023-221 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAMUSCULAR NDA 29 sections
ERTAPENEM SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 43598-901 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAVENOUS ANDA 25 sections
ertapenem HUMAN PRESCRIPTION DRUG LABEL 1 44567-820 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 28 sections
Ertapenem HUMAN PRESCRIPTION DRUG LABEL 1 44647-051 INJECTION 1 g INTRAVENOUS ANDA 29 sections
Ertapenem HUMAN PRESCRIPTION DRUG LABEL 1 51810-504 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 28 sections
Ertapenem Human Prescription Drug Label 1 55150-282 INJECTION 1 g INTRAVENOUS ANDA 25 sections
Ertapenem Human Prescription Drug Label 1 55150-282 INJECTION 1 g INTRAVENOUS ANDA 25 sections
Ertapenem HUMAN PRESCRIPTION DRUG LABEL 1 60505-6196 INJECTION 1 g INTRAVENOUS ANDA 29 sections
Ertapenem HUMAN PRESCRIPTION DRUG LABEL 1 63323-823 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAVENOUS ANDA 29 sections
Ertapenem HUMAN PRESCRIPTION DRUG LABEL 1 68001-408 INJECTION 1 g INTRAVENOUS ANDA 29 sections
Ertapenem Human Prescription Drug Label 1 68083-351 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAVENOUS ANDA 25 sections
Ertapenem HUMAN PRESCRIPTION DRUG LABEL 1 72266-159 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 25 sections